pre-update Archives

Poster

Dynamic Target-Mediated Drug Disposition (TMDD)

Abstract Methods: We have developed a novel pharmacokinetic model, termed dynamic TMDD, to mechanistically describe the…

CertaraSeptember 16, 2024

Poster

Semi-mechanistic Model of ATG-101, a PD-L1/4-1BB Bispecific Antibody, for Treatment of Solid Tumors

Abstract Trimer formation is key to the pharmacology of the bispecific ATG-101 but is difficult…

CertaraSeptember 16, 2024

Poster

Blinatumomab Trimer Formation

Insights from a Mechanistic PKPD Model on the Implications for Switching from Infusion to Subcutaneous…

CertaraSeptember 16, 2024

On-Demand Webinar

Quantitative Systems Pharmacology (QSP) Enabled First-in-Human Study in Oncology

CertaraSeptember 16, 2024

Press Coverage

Industry Sense – Drug Repurposing Unlocking New Therapeutic Possibilities

Panelists: Adekemi Taylor, PhD, VP, Quantitive Science Services at CertaraJoab Williamson, Director of Clinical Operations,…

CertaraSeptember 16, 2024

Publication

A tutorial on physiologically based pharmacokinetic approaches in lactation research

The tutorial by Amita Pansari, Xian Pan, Lisa M. Almond, and Karen Rowland-Yeo examines the…

CertaraSeptember 16, 2024

Blog

All You Need to Know About Non-CRF Data in Clinical Trials

We look at the role of non-CRF data in clinical trials, and best practices for…

CertaraSeptember 16, 2024

Blog

The SDTM Mapping Process Simplified

SDTM mapping can be one of the most challenging programming problems in a clinical trial…

CertaraSeptember 16, 2024

Blog

What Are SDTM Supplemental Qualifiers?

We touched on the SDTM supplemental qualifier in the SDTM mapping process simplified. In this…

CertaraSeptember 16, 2024

Video

From Development to Patient Impact: Biohaven’s Nurtec™ Success Story

To learn more about Biohaven's success story, read our case study. Read the case study

CertaraSeptember 13, 2024

pre-update

Dynamic Target-Mediated Drug Disposition (TMDD)

Semi-mechanistic Model of ATG-101, a PD-L1/4-1BB Bispecific Antibody, for Treatment of Solid Tumors

Blinatumomab Trimer Formation

Quantitative Systems Pharmacology (QSP) Enabled First-in-Human Study in Oncology

Industry Sense – Drug Repurposing Unlocking New Therapeutic Possibilities

A tutorial on physiologically based pharmacokinetic approaches in lactation research

All You Need to Know About Non-CRF Data in Clinical Trials

The SDTM Mapping Process Simplified

What Are SDTM Supplemental Qualifiers?

From Development to Patient Impact: Biohaven’s Nurtec™ Success Story

Newsletter sign up

Quick links

Solutions

Contact